Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomized Double Blind Placebo-Controlled Study To Assess The Effects Of FeraMax When Administered Orally Once A Day On Postoperative Fatigue Levels In Patients Following Elective Coronary Artery Bypass Graft Surgery (CABG)

NCT01912261 is registered in ClinicalTrials.gov with Nova Scotia Health Authority as lead sponsor.

NCT NCT01912261
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01912261 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomized Double Blind Placebo-Controlled Study To Assess The Effects Of FeraMax When Administered Orally Once A Day On Postoperative Fatigue Levels In Patients Following Elective Coronary Artery Bypass Graft Surgery (CABG)
Lead sponsor
Nova Scotia Health Authority
Phase
Phase 3
Overall status
Terminated
Start date
December 16, 2014
Completion date
February 28, 2019
Enrollment
121 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

fatigue